These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 27181275)

  • 21. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
    van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
    Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
    Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Lešnjaković L; Ganoci L; Bilić I; Šimičević L; Mucalo I; Pleština S; Božina N
    Pharmacogenomics; 2023 Jan; 24(2):93-106. PubMed ID: 36636997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
    De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
    Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
    Jolivet C; Nassabein R; Soulières D; Weng X; Amireault C; Ayoub JP; Beauregard P; Blais N; Carrier C; Cloutier AS; Desnoyers A; Lemay AS; Lemay F; Loungnarath R; Jolivet J; Letendre F; Tehfé M; Vadnais C; Viens D; Aubin F
    Oncologist; 2021 Apr; 26(4):e597-e602. PubMed ID: 33274825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
    Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
    Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
    Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
    Morris SA; Moore DC; Musselwhite LW; Lopes KE; Hamilton A; Steuerwald N; Hanson SL; Larck C; Swift K; Smith M; Kadakia KC; Chai S; Hwang JJ; Patel JN
    Am J Health Syst Pharm; 2023 Sep; 80(19):1342-1349. PubMed ID: 37235983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
    Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Ragia G; Biziota E; Koukaki T; Amarantidis K; Manolopoulos VG
    Pharmacogenomics; 2024 Jan; 25(2):59-67. PubMed ID: 38353109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
    Saif MW
    Cancer Genomics Proteomics; 2013; 10(2):89-92. PubMed ID: 23603345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
    Meulendijks D; Cats A; Beijnen JH; Schellens JH
    Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a
    Ockeloen CW; Raaijmakers A; Hijmans-van der Vegt M; Bierau J; de Vos-Geelen J; Willemsen AE; van den Bosch BJ; Coenen MJ
    J Oncol Pharm Pract; 2023 Jan; 29(1):5-13. PubMed ID: 34797200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Madi A; Fisher D; Maughan TS; Colley JP; Meade AM; Maynard J; Humphreys V; Wasan H; Adams RA; Idziaszczyk S; Harris R; Kaplan RS; Cheadle JP
    Eur J Cancer; 2018 Oct; 102():31-39. PubMed ID: 30114658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
    Medwid S; Wigle TJ; Kim RB
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
    Shakeel F; Fang F; Kwon JW; Koo K; Pasternak AL; Henry NL; Sahai V; Kidwell KM; Hertz DL
    Pharmacogenomics; 2021 Feb; 22(3):145-155. PubMed ID: 33410339
    [No Abstract]   [Full Text] [Related]  

  • 37. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
    Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
    J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (
    Nguyen DG; Morris SA; Hamilton A; Kwange SO; Steuerwald N; Symanowski J; Moore DC; Hanson S; Mroz K; Lopes KE; Larck C; Musselwhite L; Kadakia KC; Koya B; Chai S; Osei-Boateng K; Kalapurakal S; Swift K; Hwang J; Patel JN
    JCO Precis Oncol; 2024 Jun; 8():e2300623. PubMed ID: 38935897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
    Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
    Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
    García-Alfonso P; Saiz-Rodríguez M; Mondéjar R; Salazar J; Páez D; Borobia AM; Safont MJ; García-García I; Colomer R; García-González X; Herrero MJ; López-Fernández LA; Abad-Santos F
    Clin Transl Oncol; 2022 Mar; 24(3):483-494. PubMed ID: 34773566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.